EMBC Class Action Notice: Embecta Hit with Securities Fraud Lawsuit over Insulin Pen Misrepresentations – Investors Urged to Contact BFA Law by August 17 Deadline

Bleichmar Fonti & Auld LLP announced a class action lawsuit against Embecta Corp alleging securities fraud regarding the company's statements about the strength of its insulin pen portfolio. The complaint references a 57.8% stock drop on May 5, 2026, which followed disappointing Q2 results, market volume softness, and a dividend reduction.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.